Views & Analysis | Perspectives on pharma industry issues

R&D

Podcast interview with Boyang Wang, the founder of Immortal Dragons

Why everyone should care about longevity, with Boyang Wang

In today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Boyang Wang, the founder of Immortal Dragons.

Patients

Hands in a circle point to the middle where EU stars are, blue background

Stronger together: The future of psychiatry in a changing Eu...

Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.

Patients

More than a discount: How intelligent copay programmes are r...

Brian Laird explains a more dynamic, data-driven approach to copay is redefining affordability, creating a new standard for balancing patient support.

R&D

Beyond proof of concept: Alzheimer’s and the next chapter of...

Research has demonstrated that some individuals at elevated risk of Alzheimer's disease can be identified before symptoms emerge.

Digital

The augmented marketer: Fusing AI and human expertise in lif...

Predictive AI is not replacing human expertise, but augmenting it.

Views & Analysis

digital interactions with healthcare professionals

Results gap between digital leaders and laggards

Karl Goossens, director of commercial analytics at Veeva Systems Europe, recently spoke with pharmaphorum, discussing how effective omnichannel execution drives revenue and productivity.

Patients

Disrupting the standard of healthcare for Bangladesh: a phar...

In this mini episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Sylvana Sinha, founder, chair, and CEO of Praava Health, Bangladesh’s fastest growing healthcare brand.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Oncology

Meeting MSL training needs in an evolving landscape

As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important.

Sales & Marketing

pharmaphorum podcast Episode 257, John Holodnak, Occam

A philosophical look at market turn in the Age of AI, with J...

John Holodnak, co-founder of Occam, discusses how AI is beginning to reshape career paths across life sciences.

Sales & Marketing

Changing Faces: Agency, consultancy, and investor, March 202...

March saw a handful of noteworthy hires in the agency, consultancy, and investor spaces.

Digital

The augmented marketer: Fusing AI and human expertise in lif...

Predictive AI is not replacing human expertise, but augmenting it.

Digital

Trends & Insights: March 2026 – A pharmaphorum industry repo...

In March's Trends & Insights report, we look across the life sciences industry at the trends behind the headline news for what's also happening.

Market Access

Health, growth & renewal: ABPI 2026 looks to UK’s future

The Association of the British Pharmaceutical Industry (ABPI)'s flagship annual conference took place on Thursday, 23rd April.

Market Access

The companies shaping the UK’s commercial landscape

Which companies are working with the government to implement the US-UK pharmaceutical trade agreement?

Oncology

From promise to practice: What must happen next for genetic ...

The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Oncology

From preclinical toxicology to clinical safety: The path for...

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

Patients

Stronger together: The future of psychiatry in a changing Eu...

Mental disorders account for a significant share of economic cost across EU Member States and the United Kingdom.

Patients

More than a discount: How intelligent copay programmes are r...

Brian Laird explains a more dynamic, data-driven approach to copay is redefining affordability, creating a new standard for balancing patient support.

Patients

pharmaphorum podcast Episode 256, Dean Erhardt, D2 Solutions

Providing patient access to new therapies, with Dean Erhardt

Dean Erhardt, founder of D2 Solutions, discusses patient access today versus the state of patient access tomorrow.

Why everyone should care about longevity, with Boyang Wang

Stronger together: The future of psychiatry in a changing Eu...

More than a discount: How intelligent copay programmes are r...

Beyond proof of concept: Alzheimer’s and the next chapter of...

The augmented marketer: Fusing AI and human expertise in lif...

Results gap between digital leaders and laggards

Disrupting the standard of healthcare for Bangladesh: a phar...

Meeting MSL training needs in an evolving landscape

A philosophical look at market turn in the Age of AI, with J...

Changing Faces: Agency, consultancy, and investor, March 202...

The augmented marketer: Fusing AI and human expertise in lif...

Trends & Insights: March 2026 – A pharmaphorum industry repo...

Health, growth & renewal: ABPI 2026 looks to UK’s future

The companies shaping the UK’s commercial landscape

From promise to practice: What must happen next for genetic ...

LSX2026: Addressing adult eye cancer, with Roi Raz

From preclinical toxicology to clinical safety: The path for...

Stronger together: The future of psychiatry in a changing Eu...

More than a discount: How intelligent copay programmes are r...

Providing patient access to new therapies, with Dean Erhardt

Why everyone should care about longevity, with Boyang Wang

Beyond proof of concept: Alzheimer’s and the next chapter of...

Changing Faces: Board of Directors and Advisory Boards, Marc...

Why everyone should care about longevity, with Boyang Wang

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks